AstraZeneca Covid-19 vaccine is 70% effective on average, data show

A researcher working on the coronavirus vaccine at the Jenner Institute

A researcher working on the coronavirus vaccine at the Jenner Institute

AstraZeneca said its COVID-19 vaccine, developed along with the University of Oxford, could be around 90% effective under one dosing regimen.

Experimental vaccines developed by United States pharmaceutical companies Pfizer and Moderna had shown around 95 percent efficacy.

An independent Data Safety Monitoring Board determined that the analysis met its primary endpoint showing protection from Covid-19 occurring 14 days or more after receiving two doses of the vaccine. The data was obtained from late-stage trials in Britain and Brazil.

The vaccine's effectiveness depended on the dosing, and fell to just 62 percent when given as two full doses rather than a half-dose first.

HEALTH Coronavirus Vaccine

"The combined analysis. resulted in an average efficacy of 70 percent", it said. All results were reportedly statistically significant.

AstraZeneca said on Monday its COVID-19 vaccine could be around 90% effective, giving the world another weapon to fight the global pandemic and potentially cheaper to make, easier to distribute and faster to scale-up than rivals.

Nevertheless, the preliminary trial results still represent a fresh breakthrough in the fight against a virus that has killed almost 1.4 million people, brought global travel to a standstill and devastated the world's economy.

The vaccine was developed by Oxford University and pharmaceutical company AstraZeneca and is one of three known treatments being trialled during the pandemic.

NY Governor warns of Covid-19 resurgence during holiday season
His brother, CNN commentator Chris Cuomo , has won Emmy's as part of the production teams behind several news programs. Now they'll officially be Emmy Award-winning... or at least International Emmy Award-winning.


The UK has secured early access to 100m doses of their vaccine - on top of 255m doses from other developers'. Another jab from Moderna is 95% effective, according to trial data.

The firm said it would look to develop up to three billion doses of the vaccine in 2021 after passing regulatory hurdles.

AstraZeneca and Oxford University announced their jab is effective in preventing many people getting ill and it has been shown to work in different age groups, including the elderly.

However, the safety of these vaccines and the conditions of their administration aren't yet clear.

Joe Biden to pick Antony Blinken as Secretary of State, say reports
The non-partisan organization includes the mayors of more than 1,400 cities, each with a population of 30,000 or more. On the campaign trail, Blinken was one of Biden's closest advisers, even on issues that went beyond foreign policy.


It said it procures more than 2 billion doses of vaccines annually for routine immunisation and outbreak response on behalf of almost 100 countries.

"The group has promised to provide the vaccine not-for-profit to developing nations", he said.

There were no hospitalized or severe cases of Covid-19 reported in the studies. By comparison, Pfizer plans to distribute its vaccine using specially designed "thermal shippers" that use dry ice to maintain temperatures of minus-70 degrees Celsius (minus-94 degrees Fahrenheit). The trials either don't measure this or they are not set up to measure it well.

Researchers say it's not clear as to why this was the case. The trials are also not created to measure whether they reduce illness in those at greater risk, such as the elderly, or those with comorbidities.

AstraZeneca COVID vaccine up to 90% effective, data shows
The vaccine, called AZD1222, was 62% effective in the 8,895 participants who received two "full" doses one month part. Mr Poonawalla's company has an agreement with the government to mass-manufacture doses of the Covid vaccine.


The data is only preliminary, there are more volunteers recruited in the trial from whom results are expected soon. The announcement of its efficacy follows news of successful vaccines from Pfizer and Moderna during November. This could explain the difference in efficacies.

Latest News